Display options
Cite
Gerlich WH. Hepatitis-B-Impfstoffe – Geschichte, Erfolge, Herausforderungen und Perspektiven. [Hepatitis B vaccines-history, achievements, challenges, and perspectives]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022;doi: 10.1007/s00103-021-03484-w.
Gerlich, W. H. (2022). Hepatitis-B-Impfstoffe – Geschichte, Erfolge, Herausforderungen und Perspektiven. [Hepatitis B vaccines-history, achievements, challenges, and perspectives]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, . https://doi.org/10.1007/s00103-021-03484-w
Gerlich, Wolfram H. "Hepatitis-B-Impfstoffe – Geschichte, Erfolge, Herausforderungen und Perspektiven." [Hepatitis B vaccines-history, achievements, challenges, and perspectives]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz vol. (2022). doi: https://doi.org/10.1007/s00103-021-03484-w
Gerlich WH. Hepatitis-B-Impfstoffe – Geschichte, Erfolge, Herausforderungen und Perspektiven. [Hepatitis B vaccines-history, achievements, challenges, and perspectives]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Jan 11; doi: 10.1007/s00103-021-03484-w. Epub 2022 Jan 11. German. PMID: 35015108.
Copy Download .nbib Format: NLM
Share it on

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Jan 11; doi: 10.1007/s00103-021-03484-w. Epub 2022 Jan 11.

[Hepatitis B vaccines-history, achievements, challenges, and perspectives].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz

[Article in German]
Wolfram H Gerlich

Affiliations

  1. Institut für Medizinische Virologie, Nationales Referenzzentrum für Hepatitis-B-Viren und Hepatitis-D-Viren, Justus-Liebig-Universität Gießen, Schubertstr. 81, 35392, Gießen, Deutschland. [email protected].

PMID: 35015108 DOI: 10.1007/s00103-021-03484-w

Abstract

The first experimental vaccinations against hepatitis B virus (HBV) were performed in 1970, even before the nature of the administered "Australia antigen" was known. Soon, it was realized that this antigen was the envelope protein (HBV surface antigen, HBsAg), and it was purified from HBV-containing human plasma. Later, it was produced in genetically engineered yeast cells. The excellent efficacy of the HBsAg vaccine was confirmed in numerous studies, particularly in newborns from HBV-infected mothers who almost always become chronic HBV carriers without vaccination. But the vaccine is also highly effective in older children and adults and has been applied worldwide since 1984, leading to a circa tenfold decrease of HBV infections in the vaccinated.Still, there are several challenges with hepatitis B vaccination. In newborns from mothers with very high virus load, the vaccine may fail. Recipients who are immunocompromised, older, smokers, or obese may not produce protective antibodies. Early studies suggested that the vaccine with HBsAg subtype adw2 also protected against infections by other subtypes, but recent observations show that the protection is weaker against heterologous subtypes. Occasionally, escape mutations may develop.Most current HB vaccines are based on the knowledge of 40 years ago and could be significantly improved. Inclusion of the currently neglected preS domains in the HBV envelope would add the most important protective T‑ and B‑cell epitopes to the vaccines. Expression of the HBsAg in mammalian cell cultures would enhance the folding of neutralizing HBsAg epitopes. Use of the regionally prevalent HBsAg subtypes would increase the protection. Optimal adjuvants and epitope carriers may enhance the immunogenicity to the level necessary for immune therapy of chronic hepatitis B.

© 2022. The Author(s).

Keywords: HBV; HBsAg; Neutralizing antibody; PreS1; Protective epitopes

References

  1. Gerlich WH (2013) Medical virology of hepatitis B: how it began and where we are now. Virol J 10(1):239. https://doi.org/10.1186/1743-422X-10-239 - PubMed
  2. Gerlich WH (2015) Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol 204:39–56. https://doi.org/10.1007/s00430-014-0373-y - PubMed
  3. Doerr HW, Gerlich WH (Hrsg) (2010) Medizinische Virologie, 2. Aufl. Thieme, Stuttgart - PubMed
  4. Lürmann A (1885) Eine Icterusepidemie. Berl Klin Wochenschr 22:20–23 - PubMed
  5. Block TM, Alter HJ, London WT, Bray M (2016) A historical perspective on the discovery and elucidation of the hepatitis B virus. Antiviral Res 131:109–123. https://doi.org/10.1016/j.antiviral.2016.04.012 - PubMed
  6. Barker LF, Murray R (1972) Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis-associated antigen. Am J Med Sci 263:27–33 - PubMed
  7. Krugman S, Giles JP, Hammond J (1967) Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 200:365–373 - PubMed
  8. Blumberg BS (2002) Hepatitis B—the hunt for a killer virus. Princeton University Press, Princeton - PubMed
  9. Prince AM (1968) An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A 60(3):814–821. https://doi.org/10.1073/pnas.60.3.814 - PubMed
  10. Krugman S, Giles JP, Hammond J (1971) Viral hepatitis, type B (MS‑2 strain). Studies on active immunization. JAMA 217:41–45 - PubMed
  11. Purcell RH, Gerin JL (1975) Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. Am J Med Sci 270:395–399 - PubMed
  12. Hilleman MR, Buynak EB, Roehm RR, Tytell AA, Bertland AU, Lampson GP (1975) Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci 270:401–404 - PubMed
  13. Buynak EB, Roehm RR, Tytell AA, Bertland AU 2nd, Lampson GP, Hilleman MR (1976) Development and chimpanzee testing of a vaccine against human hepatitis B. Proc Soc Exp Biol Med 151:694–700 - PubMed
  14. Maupas P, Goudeau A, Coursaget P, Drucker J, Bagros P (1976) Immunisation against hepatitis B in man. Lancet 1(7974):1367–1370 - PubMed
  15. Szmuness W, Stevens CE, Harley EJ (1980) Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 303:833–841 - PubMed
  16. Thomssen R, Gerlich W, Böttcher U et al (1982) Preparation and testing of a hepatitis B vaccine. Dtsch Med Wochenschr 107:125–131 - PubMed
  17. Tabor E, Buynak E, Smallwood LA, Snoy P, Hilleman M, Gerety RJ (1983) Inactivation of hepatitis B virus by three methods: treatment with pepsin, urea, or formalin. J Med Virol 11:1–9 - PubMed
  18. Coutinho RA, Lelie N, Albrecht-Van Lent P et al (1983) Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. Br Med J (Clin Res Ed) 286(6374):1305–1308 - PubMed
  19. Beasley RP, Hwang LY, Lin CC, Stevens CE, Wang KY, Sun TS, Hsieh FJ, Szmuness W (1981) Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial. Lancet 2(8243):388–393 - PubMed
  20. Maupas P, Chiron JP, Barin F, Coursaget P, Goudeau A, Perrin J, Denis F, Mar ID (1981) Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet 1(8215):289–292 - PubMed
  21. Peterson DL, Roberts IM, Vyas GN (1977) Partial amino acid sequence of two major component polypeptides of hepatitis B surface antigen. Proc Natl Acad Sci USA 74:1530–1534 - PubMed
  22. Vyas GN, Rao KR, Ibrahim AB (1972) Australia antigen (hepatitis B antigen): a conformational antigen dependent on disulfide bonds. Science 178(4067):1300–1301. https://doi.org/10.1126/science.178.4067.1300 - PubMed
  23. Robinson WS, Clayton DA, Greenman RL (1974) DNA of a human hepatitis B virus candidate. J Virol 14:384–391 - PubMed
  24. Charnay P, Pourcel C, Louise A, Fritsch A, Tiollais P (1979) Cloning in escherichia coli and physical structure of hepatitis B virion DNA. Proc Natl Acad Sci USA 76:2222–2226 - PubMed
  25. Burrell CJ, Mackay P, Greenaway PJ, Hofschneider PH, Murray K (1979) Expression in escherichia coli of hepatitis B virus DNA sequences cloned in plasmid pBR322. Nature 279:43–47 - PubMed
  26. Valenzuela P, Gray P, Quiroga M, Zaldivar J, Goodman HM, Rutter WJ (1979) Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. Nature 280:815–819 - PubMed
  27. Will H, Cattaneo R, Koch HG et al (1982) Cloned HBV DNA causes hepatitis in chimpanzees. Nature 299(5885):740–742. https://doi.org/10.1038/299740a0 - PubMed
  28. Dubois MF, Pourcel C, Rousset S, Chany C, Tiollais P (1980) Excretion of hepatitis B surface antigen particles from mouse cells transformed with cloned viral DNA. Proc Natl Acad Sci U S A 77:4549–4553 - PubMed
  29. Stevens CE, Toy P, Kamili S, Taylor PE, Tong MJ, Xia GL, Vyas GN (2017) Eradicating hepatitis B virus: the critical role of preventing perinatal transmission. Biologicals 50:3–19. https://doi.org/10.1016/j.biologicals.2017.08.008 - PubMed
  30. Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A (1989) Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 261:3278–3281 - PubMed
  31. Ho JK, Jeevan-Raj B, Netter HJ (2020) Hepatitis B virus (HBV) subviral particles as protective vaccines and vaccine platforms. Viruses 12(2):126. https://doi.org/10.3390/v12020126 - PubMed
  32. Beran J (2008) Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 8(2):235–247. https://doi.org/10.1517/14712598.8.2.235 - PubMed
  33. Amjad W, Alukal J, Zhang T, Maheshwari A, Thuluvath PJ (2021) Two-dose hepatitis B vaccine (Heplisav-B) results in better seroconversion than three-dose vaccine (Engerix-B) in chronic liver disease. Dig Dis Sci 66(6):2101–2106. https://doi.org/10.1007/s10620-020-06437-6 - PubMed
  34. Awad AM, Ntoso A, Connaire JJ et al (2021) An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) in adults receiving hemodialysis. Vaccine 39(25):3346–3352. https://doi.org/10.1016/j.vaccine.2021.05.003 - PubMed
  35. Vesikari T, Langley JM, Segall N et al (2021) Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(20)30780-5 - PubMed
  36. Safadi R, Khoury T, Saed N et al (2021) Efficacy of birth dose vaccination in preventing mother-to-child transmission of hepatitis B: a randomized controlled trial comparing Engerix‑B and sci-B-Vac. Vaccines (Basel) 9(4):331. https://doi.org/10.3390/vaccines9040331 - PubMed
  37. Shouval D, Roggendorf H, Roggendorf M (2015) Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol 204(1):57–68. https://doi.org/10.1007/s00430-014-0374-x - PubMed
  38. Cornelius C, Schöneweis K, Georgi F et al (2016) Immunotherapy with the preS-based grass pollen allergy vaccine BM32 induces antibody responses protecting against hepatitis B infection. EBioMedicine 11:58–67 - PubMed
  39. Tulaeva I, Cornelius C, Zieglmayer P et al (2020) Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32. EBioMedicine 59:102953. https://doi.org/10.1016/j.ebiom.2020.102953 - PubMed
  40. World Health Organization (2021) Global progress report on HIV, viral hepatitis and sexually transmitted infections (2021) Accountability for the global health sector strategies 2016–2021: actions for impact. World Health Organization, Geneva (Licence: CC BY-NC-SA 3.0 IGO) - PubMed
  41. World Health Organization (2017) Global hepatitis report 2017. World Health Organization, Geneva (Licence: CC BY-NC-SA 3.0 IGO) - PubMed
  42. Chen DS (2010) Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol 25(1):19–25. https://doi.org/10.1111/j.1440-1746.2009.06165.x - PubMed
  43. Wu TW, Lin HH, Wang LY (2013) Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology 57:37–45. https://doi.org/10.1002/hep.25988 - PubMed
  44. Chang MH, You SL, Chen CJ, Taiwan Hepatoma Study Group et al (2009) Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 101(19):1348–1355. https://doi.org/10.1093/jnci/djp288 - PubMed
  45. Pan CQ et al (2016) Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 374(24):2324–2334 - PubMed
  46. Jourdain G et al (2018) Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med 378:911–923 - PubMed
  47. Miyakawa M, Yoshida LM, Nguyen HT et al (2021) Hepatitis B virus infection among pregnant mothers and children after the introduction of the universal vaccination program in Central Vietnam. Sci Rep 11(1):8676. https://doi.org/10.1038/s41598-021-87860-1 - PubMed
  48. World Health Organization (2020) Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy. World Health Organization, Geneva (Licence: CCBY-NC-SA 3.0 IGO) - PubMed
  49. Cornberg M et al (2021) S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion. Z Gastroenterol 59:691–776. https://doi.org/10.1055/a-1498-2512 - PubMed
  50. Robert Koch Institut (2013) Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2013. Epidemiol Bull 2013(34):313–344 - PubMed
  51. Gerlich WH, Glebe D, Kramvis A, Magnius LO (2020) Peculiarities in the designations of hepatitis B virus genes, their products, and their antigenic specificities: a potential source of misunderstandings. Virus Genes 56(2):109–119. https://doi.org/10.1007/s11262-020-01733-9 - PubMed
  52. Kramvis A (2014) Genotypes and genetic variability of hepatitis B virus. Intervirology 57(3):141–150. https://doi.org/10.1159/000360947 - PubMed
  53. Szmuness W, Stevens CE, Harley EJ et al (1982) Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 307(24):1481–1486. https://doi.org/10.1056/NEJM198212093072403 - PubMed
  54. Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain J‑P, Gerlich W (2011) Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 364:236–247 - PubMed
  55. Wen WH, Chen HL, Ni YH, Hsu HY, Kao JH, Hu FC, Chang MH (2011) Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. Hepatology 53:429–436 - PubMed
  56. Ye H, Teng J, Lin Z et al (2020) Analysis of HBsAg mutations in the 25 years after the implementation of the hepatitis B vaccination plan in China. Virus Genes 56:546–556. https://doi.org/10.1007/s11262-020-01773-1 - PubMed
  57. Koyama T, Matsuda I, Sato S, Yoshizawa H (2003) Prevention of perinatal hepatitis B virus transmission by combined passive-active immunoprophylaxis in Iwate, Japan (1981–1992) and epidemiological evidence for its efficacy. Hepatol Res 26(4):287–292. https://doi.org/10.1016/s1386-6346(03)00168-2 - PubMed
  58. Salpini R, Colagrossi L, Bellocchi MC et al (2015) Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology 61(3):823–833. https://doi.org/10.1002/hep.27604 - PubMed
  59. Feeney SA, McCaughey C, Watt AP et al (2013) Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient. J Med Virol 85:597–601 - PubMed
  60. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Srinivasa K, Hutagalung Y, Bock HL, Hoet B (2009) Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers. J Infect Dis 200(1):33–38. https://doi.org/10.1086/599331 - PubMed
  61. Mitteilung der Ständigen Impfkommission (2013) Wissenschaftliche Begründung für die Änderung der Empfehlung zur Impfung gegen Hepatitis B. Epidemiol Bull 36/37:371–381 - PubMed
  62. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH (1984) Large surface proteins of hepatitis B virus containing the pre‑S sequence. J Virol 52:396–402 - PubMed
  63. Milich DR, McLachlan A, Thornton GB (1987) T‑cell recognition of pre‑S regions of HBsAg can bypass nonresponse to the S region. Adv Exp Med Biol 225:233–239. https://doi.org/10.1007/978-1-4684-5442-0_20 - PubMed
  64. Stamm B, Gerlich W, Thomssen R (1980) Quantitative determination of antibody against hepatitis B surface antigen: measurement of its binding capacity. J Biol Stand 8:59–68 - PubMed
  65. Bremer CM, Sominskaya I, Skrastina D et al (2011) N‑terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus. J Hepatol 55(1):29–37. https://doi.org/10.1016/j.jhep.2010.10.019 - PubMed
  66. Whitacre DC, Peters CJ, Sureau C et al (2020) Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance. Hum Vaccin Immunother 16(2):251–268. https://doi.org/10.1080/21645515.2019.1689745 - PubMed
  67. Leroux-Roels G, Marchant A, Levy J et al (2016) Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial. Clin Immunol 169:16–27. https://doi.org/10.1016/j.clim.2016.05.007 - PubMed
  68. Li D, Wenhui H, Ximing L (2017) A potent human neutralizing antibody Fc-dependently reduces established HBV infections. Elife 6:e26738. https://doi.org/10.7554/eLife.26738 - PubMed
  69. Hehle V, Beretta M, Bourgine M et al (2020) Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers. J Exp Med 217(10):e20200840. https://doi.org/10.1084/jem.20200840 - PubMed

Publication Types